their latest acquisition is doing well. Guidance overall for 2024 went from $3.19 to avg $3.05. Disappointed to hear the Boston Factory devices are no longer in guidance at all. Hard to know how to value the stock now, but very cheap at a 9 PE going forward vs the sector avg 20+ PE going forward. Here is the bad news...
Boston Update
Third-party audit yielded more findings than anticipated
Currently evaluating the timeline to address the findings and resume commercial distribution
Removing SurgiMend and PriMatrix from 2024 guidance
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.